A major review published in The Lancet has confirmed that mRNA vaccines are a safe and effective medical technology, based on evidence from laboratory research, clinical trials, and real-world safety monitoring.
The review examined more than two decades of mRNA vaccine research and data from billions of vaccine doses administered worldwide. Researchers concluded that serious adverse events are rare and are significantly outweighed by the protection these vaccines provide against severe disease, hospitalisation, and death.
mRNA vaccines gained global attention during the COVID-19 pandemic, but the technology behind them had been in development for over 20 years. These vaccines work by delivering temporary genetic instructions that allow the body’s cells to produce a target protein, helping the immune system recognise and respond to future infections.
The review found that vaccine mRNA does not enter the cell nucleus and does not alter human DNA. The mRNA and lipid nanoparticles used in the vaccines remain in the body temporarily before being naturally broken down. Researchers noted that this process supports the strong safety profile of the technology.
Most reported vaccine reactions, including fatigue, fever, and pain at the injection site, were mild to moderate and typically resolved within a few days. Rare side effects, including myocarditis and severe allergic reactions, have been identified through extensive safety monitoring but occur at very low rates.
The researchers also highlighted the effectiveness of mRNA vaccines in reducing serious health outcomes. Early clinical trials showed that COVID-19 mRNA vaccines provided strong protection, while large-scale real-world studies demonstrated significant reductions in infection, hospitalisation, and death, particularly during periods when protection against severe disease remained high.
Although immunity against infection can decrease over time and with the emergence of new variants, booster doses have helped strengthen protection. The review emphasised that continued monitoring and transparent communication are essential for maintaining trust and improving future vaccine programmes.
The success of mRNA vaccines has opened new possibilities beyond COVID-19. Scientists are developing mRNA-based vaccines for diseases including influenza, respiratory syncytial virus (RSV), tuberculosis, and other infectious conditions. Researchers are also exploring the use of mRNA technology in personalised cancer vaccines and treatments for certain rare genetic disorders.
Experts caution that mRNA technology is not a universal solution for all diseases. Further research is needed to improve durability of protection, reduce potential side effects, and make manufacturing more efficient and affordable.
The review also pointed to the importance of expanding global access to mRNA technologies. Improving manufacturing capacity, supporting technology transfer, and strengthening healthcare systems will be essential to ensuring that future vaccines and treatments reach communities worldwide.
The latest evidence reinforces the role of mRNA vaccines as a significant advancement in modern medicine. With continued innovation, safety surveillance, and international cooperation, mRNA technology could contribute to preventing more diseases and developing new medical treatments in the years ahead.
